Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NPS-1034 |
Synonyms | |
Therapy Description |
NPS-1034 inhibits AXL and MET, including mutant forms of MET, as well as other kinases, which potentially results in decreased tumor cell growth and may overcome MET or AXL mediated drug resistance (PMID: 24173966, PMID: 24165158). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NPS-1034 | AXL Inhibitor 30 MET Inhibitor 59 | NPS-1034 inhibits AXL and MET, including mutant forms of MET, as well as other kinases, which potentially results in decreased tumor cell growth and may overcome MET or AXL mediated drug resistance (PMID: 24173966, PMID: 24165158). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 rearrange | lung non-small cell carcinoma | sensitive | NPS-1034 | Preclinical - Cell culture | Actionable | In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158). | 24165158 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|